Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Louis Diehl

Phase II Open Label Study of the Oral Vascular Endothelial Growth Factor-Receptor Inhibitor PTK787/ZK222584 (Vatalanib) in Adult Patients With Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2013English

Related publications

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology
MedicineHematology
2013English

Differential Effects of the Vascular Endothelial Growth Factor Receptor Inhibitor PTK787/ZK222584 on Tumor Angiogenesis and Tumor Lymphangiogenesis

Molecular Cancer Therapeutics
Cancer ResearchOncology
2009English

Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Long-Term Follow-Up of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

Current Oncology
Oncology
2019English

A Phase Iia Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy